MD3 COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM'S PERSPECTIVE IN AUSTRIA  by Tuschel, A et al.
MD3
COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY
VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM’S
PERSPECTIVE IN AUSTRIA
Tuschel A, Meissl M, Ogon M
Orthopaedic Hospital Vienna Speising,Vienna, Austria
OBJECTIVES: Chronic low back pain caused by disc degen-
eration (“degenerative disc disease”) is one of the most
common causes for doctor visits in western industrial countries
and presents an immense economic burden both to the indi-
vidual and to society. In many cases, surgery can be a treatment
option. For some indications, “lumbar disc arthroplasty” may
be an innovative alternative to the current gold-standard,
“lumbar fusion” and recent clinical studies have shown at least
its non-inferiority for short- and midterm follow-up The aim of
this investigation was to analyse cost-effectiveness of “lumbar
disc arthroplasty” versus “lumbar fusion” form a health care
system’s perspective. METHODS: A decision model including
treatment paths and associated direct costs (surgery, inpatient
stays, outpatient visits, GP and orthopaedic consultations,
x-ray, medication, rehabilitation and physiotherapy) over a
12-months time horizon was developed. Main outcomes were
clinical success (measured by Oswestry-Disability-Index (ODI)
and SF-36 at 1 year follow-up) and costs in Euros (€). Clinical
input data was derived from a recently performed matched-
cohort-study and a meta-analysis of further four trials com-
paring the two treatment options. Costs were derived from
standard Austrian price lists and from hospital’s cost unit
accounting. RESULTS: Disc arthroplasty showed statistically
signiﬁcant better outcome-scores at 1 year-follow up, while at
the same time caused lower costs than lumbar fusion: Costs per
improved ODI-point were 918€ in the fusion group and €519
in patients treated with lumbar disc arthroplasty. Costs for one
gained SF36-point were €1500 after fusion and €866€ after disc
arhroplasty. CONCLUSIONS: For a period of 1 year after
surgery, this study suggests that lumbar disc arthroplasty is a
cost-effective treatment compared with lumbar fusion from a
health care system’s perspective in Austria. Further studies,
including longer follow-up and indirect-costs, are necessary
for the assessment of cost-effectiveness from the societal
perspective.
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OBJECTIVES: Managing stroke of undetermined aetiology (or
“cryptogenic stroke”) poses complex therapeutic decisions for
physicians. In the absence of a clear diagnosis, effective measures
of preventing stroke recurrence may be missed. AF is estimated to
be present in a signiﬁcant portion of these patients. Adding an
ICM to standard diagnostics allows physicians to maximize AF
detection yield, administer targeted and appropriate care, and
efﬁciently prevent stroke recurrence. We sought to examine the
cost-effectiveness of this strategy, under the UK NHS setting.
METHODS: Literature Review of OAC Usage and HRQoL
Effects; Stroke HRQoL Effects; and, AF Monitoring and Costs.
TreeAge Pro Version 8 was used to develop a Markov Decision
Model, analysed using Monte Carlo simulations. The payer per-
spective was used. Cost calculations based on UK NHS Reference
Costs. RESULTS: Depending on the year of the analysis, the
ICM-based strategy ranged from highly cost-effective to domi-
nant. The total costs associated with the ICM-based strategy
were £24,278 vs. £28,062 for standard practice. The total effect
of the ICM-based strategy was 14,623 QALYs vs. 14,107
QALYs. CONCLUSIONS: Using ICMs to diagnose AF in
patients with stroke of unknown aetiology dominates current
practice even if all such patients receive a device. Therefore, there
can be little doubt that using these devices to uncover AF within
the studied population can potentially be highly cost-effective.
Moving forward, further research is required to identify the
speciﬁc patient sub-groups in which implanting the ICM
combines maximized economic value with practicality and
affordability.
PODIUM SESSION I: PERFORMANCE OF
HTA AGENCIES
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A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS,
PROCEDURES,AND IMPACT ACROSS HTA AGENCIES
Schwarzer R, Siebert U
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OBJECTIVES: 1) To develop a systematic framework for
describing and comparing different features of HTA agencies in a
formal and explicit manner; 2) to summarize and categorize these
features for selected HTA agencies; 3) to describe and discuss
similarities and differences between the agencies by comparison;
and 4) to draw conclusions both for producers and users of HTA
in research, policy and practice. METHODS: We performed a
systematic literature search, added information from HTA
agencies and developed a conceptual framework comprising
eight main domains: 1) organization; 2) scope; 3) processes; 4)
methods; 5) dissemination; 6) decision; 7) implementation; and
8) impact. We grouped relevant subunits of these domains in an
evidence table. We chose ﬁve HTA agencies to test our frame-
work: IQWiG, DAHTA@DIMDI, NICE, HAS and SBU. The
results were interpreted within and compared across agencies by
demonstrating similarities and differences. RESULTS: We devel-
oped a framework representing a comprehensive structure sur-
rounding HTA and the stages through which a HTA is passing
from science to policy and then impacts the population. We
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